Lifecore Biomedical (LFCR) director Obus received 25,907 shares
Insider transactions reported
Nelson Obus (director at Lifecore Biomedical Inc., LFCR) reported that they received 25,907 shares on Jun 4, 2026. After these transactions the filing shows 164,100 shares held directly.
- Reporting person
- Obus Nelson
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Grant or award (A) | Common Stock1, 2 | +25,907 | - | - | 164,100 direct |
Holdings before and after
- Common Stock: 138,193 to 164,100 direct
Footnotes from the filing
- 1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
- 2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Obus report in this LFCR Form 4?
Nelson Obus (director at Lifecore Biomedical Inc., LFCR) reported that they received 25,907 shares on Jun 4, 2026. After these transactions the filing shows 164,100 shares held directly.
How many LFCR shares does Obus hold after this filing?
The filing shows 164,100 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for LFCR
Across the 25 sessions after earlier LFCR headlines, the stock closed higher 13 times and lower 12 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LFCR | SPY |
|---|---|---|---|
| Jun 2, 2026 | Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer | +12.4% | +0.1% |
| May 21, 2026 | Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference | +9.0% | +0.2% |
| May 13, 2026 | Lifecore Biomedical to Participate at CDMO Live Europe | -1.3% | +0.6% |
| May 6, 2026 | Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update | -3.9% | +1.4% |
| Apr 30, 2026 | Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026 | +2.6% | +1.0% |
| Apr 23, 2026 | Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -5.9% | -0.4% |
Earlier insider filings at LFCR
- Jun 5, 2026Director Aryeh Jason was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Jun 5, 2026Director Korenberg Matthew E was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Jun 5, 2026Director Schechter Joshua was granted 25,907 shares, increasing direct ownership by 24% to 133,080 units (SEC Form 4)
- Jun 5, 2026Director Antunes Humberto Calheiros was granted 25,907 shares, increasing direct ownership by 55% to 72,967 units (SEC Form 4)
- Jun 5, 2026Director Johnson Paul Harold was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow LFCR and get a push notification the moment its next story breaks.